# Future Features Queue

## High-Impact Additions (Prioritized)

### Tier 1: Immediate Value ⭐⭐⭐

#### 1. Real-Time Trial Monitoring Dashboard
**Value:** Actionable signals for portfolio management  
**Effort:** Medium  
**Features:**
- Daily ClinicalTrials.gov diff tracking
- Alert system for status changes (enrollment, completion, termination)
- Enrollment velocity tracking
- Site activation monitoring
- Email/SMS notifications for key events

#### 2. NLP on Trial Protocols
**Value:** Automated intelligence extraction from unstructured data  
**Effort:** High  
**Features:**
- Endpoint extraction (primary, secondary)
- Intervention classification (drug, device, behavioral)
- Eligibility criteria parsing
- Adverse event prediction from protocol text
- Semantic similarity search across trials

#### 3. Synthetic Control Arms
**Value:** Cutting-edge methodology, FDA-relevant, publishable  
**Effort:** High  
**Features:**
- Build synthetic control groups from historical data
- Regulatory-grade methodology (FDA guidance)
- Bayesian hierarchical models
- Cost-benefit analysis for trial sponsors
- Validation against real RCT data

---

### Tier 2: Strategic Intelligence

#### 4. Competitive Landscape Mapping
**Value:** Strategic intelligence for capital allocators  
**Effort:** Medium  
**Features:**
- Identify overlapping trial populations
- Track sponsor strategy shifts over time
- Detect emerging therapeutic approaches
- Market concentration metrics (HHI, CR4)
- Competitive positioning analysis

#### 5. Drug Repurposing Intelligence
**Value:** Investment opportunities in off-patent drugs  
**Effort:** Medium  
**Features:**
- Mechanism of action (MOA) similarity
- Target pathway overlap analysis
- Adverse event profile matching
- Clinical trial outcome correlation
- Patent expiry tracking

#### 6. Regulatory Pathway Prediction
**Value:** Timeline and risk assessment for investors  
**Effort:** Medium  
**Features:**
- Breakthrough therapy designation likelihood
- Accelerated approval pathway eligibility
- REMS requirement prediction
- Advisory committee outcome forecasting
- FDA review timeline estimation

---

### Tier 3: Operational Intelligence

#### 7. Patient Recruitment Feasibility
**Value:** Operational intelligence for sponsors  
**Effort:** Medium  
**Features:**
- Geographic prevalence mapping
- Investigator experience scoring
- Enrollment velocity prediction
- Competitive trial burden analysis
- Site selection optimization

#### 8. Bayesian Clinical Trial Forecasting
**Value:** Probabilistic forecasts with uncertainty quantification  
**Effort:** High  
**Features:**
- Prior beliefs from historical trial data
- Real-time Bayesian updating as trials progress
- Credible intervals for decision-making
- Integration with survival analysis
- Monte Carlo simulation for scenarios

---

### Tier 4: Precision Medicine

#### 9. Biomarker Enrichment Analysis
**Value:** Precision medicine investment thesis  
**Effort:** High  
**Features:**
- Subgroup identification from trial results
- Biomarker-outcome associations
- Responder vs non-responder profiling
- Companion diagnostic opportunities
- Predictive biomarker validation

#### 10. Economic Value Modeling
**Value:** Commercial viability assessment  
**Effort:** Medium  
**Features:**
- QALY/DALY calculations
- Cost-effectiveness thresholds by country
- Payer coverage prediction
- Market access probability
- Pricing strategy optimization

---

## Quick Wins (Low Effort, High Impact)

### UI/UX Enhancements
1. **Trial Timeline Visualization** - Gantt charts showing phase progression
2. **Sponsor Portfolio View** - All trials by company with success rates
3. **Geographic Heatmaps** - Trial site locations and enrollment density
4. **Endpoint Taxonomy** - Standardized endpoint classification
5. **Alert System** - Email notifications for trial status changes

### Data Enhancements
6. **Patent Linkage** - Connect trials to patent expiry dates
7. **Publication Linking** - Auto-link to PubMed results
8. **ClinicalTrials.gov History** - Track changes over time
9. **Investigator Network** - Map PI relationships and experience
10. **Indication Expansion Tracking** - Monitor label expansion strategies

---

## Implementation Strategy

### Phase 4A: Validation (Before Building)
- Deploy to Streamlit Cloud
- Get 10 real users (5 investors, 3 scientists, 2 advocates)
- Measure engagement and feature usage
- Identify top 3 most-requested features

### Phase 4B: Prioritized Build
- Build #1 most-requested feature
- Validate with users
- Iterate based on feedback
- Repeat

### Phase 4C: Scale
- Add features based on validated demand
- Optimize for performance
- Build API for programmatic access
- Consider enterprise features

---

## Decision Framework

**Build a feature if:**
- ✅ 3+ users explicitly request it
- ✅ It serves all three stakeholder groups
- ✅ It uses real data (no synthetic)
- ✅ It's technically feasible with current infrastructure
- ✅ It maintains Stanford PhD-level rigor

**Don't build if:**
- ❌ Only 1 user wants it
- ❌ It's a "nice to have" without clear value
- ❌ It requires synthetic data
- ❌ It compromises transparency or rigor
- ❌ It's premature optimization

---

## Notes

**Current Status:** Production-ready platform with 6,819 verified trials, advanced analytics, and institutional-grade positioning.

**Next Step:** User validation before building more features.

**Philosophy:** Data-driven development. Build what users actually need, not what we imagine they want.

---

*Queue created: 2026-05-25*  
*Status: Awaiting user validation phase*
